Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohns disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçets disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.Common side effects include infections, acute infusion reactions, and abdominal pain. Infliximab is a chimeric monoclonal antibody biologic. It seems to work by binding to and neutralizing TNF-α, preventing it from interacting with its receptors on the cell. TNF-α is a chemical messenger (cytokine) and a key part of the autoimmune reaction. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a "chimeric monoclonal antibody".Infliximab was approved for medical use in the United States in 1998, and in the European Union in August 1999. Infliximab biosimilars have been approved in the EU (2013), in Japan (2014), and in the United States (2016, 2017, 2019). It is on the World Health Organizations List of Essential Medicines.
In the case of R v Jarvis, the Supreme Court of Canada held that for the purposes of that law, the expectation of privacy is not all-or-nothing; rather there are degrees of privacy, and although secondary-school pupils in the school building cannot reasonably expect as much privacy as in the bedroom, nonetheless they can expect enough privacy so that photographing them without their consent for the purpose of sexual gratification is forbidden.In some countries voyeurism is considered to be a sex crime. In the United Kingdom, for example, non-consensual voyeurism became a criminal offence on May 1, 2004. In the English case of R v Turner (2006), the manager of a sports centre filmed four women taking showers. There was no indication that the footage had been shown to anyone else or distributed in any way. The defendant pleaded guilty. The Court of Appeal confirmed a sentence of nine months imprisonment to reflect the seriousness of the abuse of trust and the traumatic effect on the victims. In another English case in 2009, R v Wilkins (2010), a man who filmed his intercourse with five of his lovers for his own private viewing was sentenced to eight months in prison and ordered to sign onto the Sex Offender Register for ten years.